Eli Lilly and Novo Stock Sold Off. Don’t Blame Their Diet Drugs.

Stock in Eli Lilly and Novo Nordisk outperformed last year, largely because of remarkable demand for new drugs that drive weight loss in patients afflicted with diabetes and obesity. Both stocks were ...

NVO Stock Jumps After Novo Nordisk Expands Diabetes Lead Over Pfizer, Eli Lilly

The Food and Drug Administration expanded the label for Novo Nordisk‘s (NVO) oral diabetes medicine, leading NVO stock to jump Friday. X Now, patients with type 2 diabetes can take Rybelsus with...

The Big Winners—and Losers —in the Inflation Bill

Senate Majority Leader Chuck Schumer (D-NY) helped shepherd the Inflation Reduction Act through the Senate after earlier bills died. Drew Angerer/Getty Images Text size The House won’t take up Democra...

NVO Stock: Obesity Sales Nearly Double, But That Wasn’t Enough For Investors

Danish drugmaker Novo Nordisk (NVO) missed second-quarter expectations Wednesday but raised its full-year outlook. NVO stock tumbled. X Sales climbed 25% to 41.27 million Danish Kroner — or about $5.6...

The Days of Big Pharma Are Over. Big Biotech Is on Its Way.

W hen GlaxoSmithKline spins off its enormous division selling drugstore staples like Advil and Tums next month, it will represent more than just the latest shuffling of assets among corporate giants. ...

GlaxoSmithKline shares soar after Unilever bids for its consumer healthcare unit

Shares of GlaxoSmithKline surged on Monday, while Unilever stock tumbled following a failed $68 billion bid by the latter to acquire the pharmaceutical giant’s consumer healthcare arm. Driving the FTS...